Tag:

Patheon

Latest Headlines

Latest Headlines

Plant that Patheon wanted to sell gets investment

A U.K. plant that the former Patheon was ready to bail on two years ago will now get a $300 million shot in the arm. It and client Pacira will partner on manufacturing suites to provide additional capacity to produce Pacira's analgesic, Exparel.

Pacira picks Patheon to hit the gas on pain drug production

Pacira Pharmaceuticals is counting on an expanded indication and swell in demand for its surgical pain treatment, and the biotech has inked a deal with contract manufacturer Patheon to collaborate on production in a multiyear agreement.

Meet DPx, the result of a $2.6B CMO merger

A $2.6 billion deal united contract manufacturers Patheon and DSM Pharmaceutical Products, and now the combined company has emerged to do business under the monicker DPx, expecting to bank $2 billion in revenue this year.

CMO born from $2.6 billion merger comes on the scene as DPx

A new company, initially dubbed NewCo and created by the $2.6 billion merger of contract manufacturer Patheon and Netherlands-based DSM Pharmaceutical Products, has officially broken onto the scene. It has been given the moniker of DPx and starts its corporate life as one of the largest contract manufacturing and development groups in the world.

UPDATED: Patheon soars in its last year as a public CMO

Contract manufacturer Patheon boosted its revenue by about 137% in the last fiscal year, hauling in more than $1 billion as it prepares to merge with competitor DSM.

Patheon's deal for DSM would transform it into the second largest CMO in the world

Private investment firm JLL Partners is orchestrating a $2.6 billion merger of its Canadian contract manufacturer Patheon ($PTI) with the Netherlands-based DSM Pharmaceutical Products on the bet that the combined company will grow in a growing niche of the industry.

UPDATED: Pharma Tech adds capacity as the CMO industry heats up

Private equity investors JLL Partners put a sharp focus on the potential in the CMO industry last month when it orchestrated a $2.6 billion deal merging two contract manufacturing companies into a global operation. It also illustrated the pressure smaller players are under to beef up if they are to compete. Pharma Tech Industries (PTI) has been doing just that.

Patheon invests in U.K. plant, posts operating loss

CMO Patheon is investing in a U.K. site to increase capacity and add capabilities, including automated capsule filling. The expansion comes as Patheon prepares to merge with DSM's pharma business under the ownership of JLL Partners.

After $2.6B deal, JLL targets more CMOs

Private equity outfit JLL Partners bet big on contract manufacturing last week with its $2.6 billion deal to combine Dutch Royal DSM with its portfolio CMO Patheon, and the fund's co-founder said the company's not done yet.

JLL expects to buy more CMOs

Paul S. Levy, co-founder of the investment group that just announced a $2.6 billion deal to buy DSM Pharmaceutical Products and merge it with Patheon, sees opportunity in rolling up more players into a larger company. But with other private investors in the market, he may find competition looking over the same targets.